Ropeginterferon Alfa-2B Shows Anti-Polycythaemia Vera Activity Without Causing Clinically Significant Anaemia

Anaemia could develop in polycythemia vera (PV) due to phlebotomy-caused iron-deficiency and cytotoxic effect of cytoreductive therapy. Ropeginterferon alfa-2b treatment was not associated with ≥grade 3 anaemia in two recent clinical studies of 78 patients with PV. Only four cases of grade 2 anaemias occurred, the anaemia resolved. The mean haemoglobin levels were above 120.0 g/L. Therefore, ropeginterferon alfa-2b treatment does not lead to clinically significant anaemia and appears to manage PV without affecting normal erythropoiesis. “Both trials were registered at clinicaltrials.gov (A19-201: NCT04182100; A20-202: NCT05485948)”.